---
document_datetime: 2026-01-09 15:00:41
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fintepla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: fintepla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.8652523
conversion_datetime: 2026-01-10 11:24:05.266945
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fintepla

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                             |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 09/01/2026                          |                                             | SmPC and PL                      | To clarify the dose rounding methodology in Section |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000316091                        | PRODUCTS - C.I.z Other variation - Accepted C.I.z (Type IB) - To clarify the dose rounding methodology in Section 4.2 of the SmPC and Section 3 of the PL, and to correct the volumes provided in the Table 2 (SmPC) and Table 1 (PL).   |            |            |                                  | 4.2 of the SmPC and Section 3 of the PL, and to correct the volumes provided in the Table 2 (SmPC) and Table 1 (PL).                                                                                                                                                   |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000296853    | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted             | 22/09/2025 | N/A        |                                  |                                                                                                                                                                                                                                                                        |
| Renewal - 5 year / EMA/R/0000256601      | - Renewal - Accepted                                                                                                                                                                                                                     | 18/09/2025 | 17/11/2025 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Fintepla in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| Variation type IA_IN / EMA/VR/0000268730 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                      | 02/05/2025 | 17/11/2025 | Annex II and PL                  |                                                                                                                                                                                                                                                                        |
| Variation type IB / EMA/VR/0000249348    | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b                                    | 14/04/2025 | N/A        |                                  |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                       | Tightening of specification limits - Accepted                                                                                                                                                                 |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000253856 | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted | 27/02/2025 | N/A |